Topical application of calcium channel blockers to reduce the progression of experimentally induced myringosclerosis and tympanosclerosis

Laryngoscope

Volumn 118, Issue 4, 2008, Pages 697-705

  Selcuk, Adin ^a,d   Akdogan, Ozgur ^a   Ozcan, Ibrahim ^a   Giray, Seren Gulsen ^b   Dere, Huseyin ^a   Ozogul, Candan ^c  

^a ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

^c DOKUZ EYLUL UNIVERSITY   (Turkey)

^d NONE   (Turkey)

Author keywords

Calcium channel blockers; Chronic otitis media; Disease models animals; Sclerosis; Tympanosclerosis

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; EAR DISEASE; EARDRUM; GUINEA PIG; INOCULATION; LAMINA PROPRIA; MALE; MICROSCOPY; MYRINGOSCLEROSIS; MYRINGOTOMY; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; TEMPORAL BONE; TOPICAL TREATMENT; TYMPANOSCLEROSIS;

ADMINISTRATION, TOPICAL; ANIMALS; CALCIUM CHANNEL BLOCKERS; DILTIAZEM; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; EAR, MIDDLE; EPITHELIUM; FIBROBLASTS; GUINEA PIGS; LEUKOCYTES, MONONUCLEAR; MALE; MUCOUS MEMBRANE; NEUTROPHILS; OTITIS MEDIA; OTOSCLEROSIS; PNEUMOCOCCAL INFECTIONS; TEMPORAL BONE; TYMPANIC MEMBRANE;

EID: 41849147562     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e31815ed115     Document Type: Article

References (35)

1. Forseni Flodin M, Hultcrantz M. Possible inflammatory mediators in tympanosclerosis development. Int J Pediatr Otorhinolaryngol 2002;63:149-154.
2. Akyildiz N. Ear Diseases and Microsurgery 1: Otitis Media. Tympanosclerosis. Ankara, Turkey: Bilimsel Tip Yayinev; 1998:461-472.
3. Mann W, Beck C, Schaefer HE. The significance of calcium channel blockers in rat experimental tympanosclerosis. Arch Otorhinolaryngol 1987;243:382-386.
4. Bhaya MH, Schachern PA, Morizono T, et al. Pathogenesis of tympanosclerosis. Otolaryngol Head Neck Surg 1993;109:413-420.
5. Forseni Flodin M. Macrophages and possible osteoclast differentiation in the rat bullar bone during experimental acute otitis media, with reference to tympanosclerosis. Otol Neurotol 2001;22:771-775.
6. Wielinga EW, Kerr AG. Tympanosclerosis [Review]. Clin Otolaryngol Allied Sci 1993;18:341-349.
7. Raustyte G, Hermansson A. Development of MS during acute otitis media caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a clinical otomicroscopical study using the rat model. Medicina 2005;41:661-667.
8. Hof RP, Ruegg UT. Calcium channel blockers in experimental atherosclerosis. Use-dependence of isradipine: a potential explanation for enhanced action in atherosclerotic animals and tissue selectivity [Review]. Am J Hypertens 1991;4:107S-113S.
9. Sowers JR Calcium channel blockers and atherosclerosis [Review]. Am J Kidney Dis 1990;16(4 Suppl 1):3-9.
10. Allanore Y, Borderie D, Perianin A, et al. Nifedipine protects against overproduction of superoxide anion by monocytes from patients with systemic sclerosis. Arthritis Res Ther 2005;7:R93-R100.
11. Mandarim-de-Lacerda CA, Pereira LM. Renal cortical remodelling by NO-synthesis blockers in rats is prevented by angiotensin-converting enzyme inhibitor and calcium channel blocker. J Cell Mol Med 2001;5:276-283.
12. Fleckenstein A, Fleckenstein-Grun G, Frey M, et al. Future directions in the use of calcium channel blockers. Am J Cardiol 1987;59:177B-187B.
13. Haller H. Calcium channel blockers and cellular mechanisms of glomerulosclerosis and atherosclerosis [Review]. Am J Kidney Dis 1993;21(6 Suppl 3):26-31.
14. Dworkin LD. Impact of calcium entry blockers on glomerular injury in experimental hypertension [Review]. Cardiovasc Drugs Ther 1990;4:1325-1330.
15. Hermansson A, Emgard P, Prellner K, et al. A rat model for pneumococcal otitis media. Am J Otolaryngol 1988;9:97-101.
16. Forseni M, Eriksson A, Bagger-Sjoback D, et al. Development of tympanosclerosis: can predicting factors be identified? Am J Otol 1997;18:298-303.
17. So HS, Park C, Kim HJ, et al. Protective effect of T-type calcium channel blocker flunarizine on cisplatin-induced death of auditory cells. Hear Res 2005;204:127-139.
18. Zhuravskii SG, Lopotko AI, Tomson VV, et al. Protective effect of calcium channel blocker verapamil on morphological and functional state of hair cells of the organ of corti in experimental kanamycin-induced ototoxicity. Bull Exp Biol Med 2002;133:404-407.
19. Shen H, Zhang B, Shin JH, et al. Prophylactic and therapeutic functions of T-type calcium blockers against noise-induced hearing loss. Hear Res 2007;226:52-60.
20. Spratley JE, Hellstrom SO, Mattsson CK, et al. Topical ascorbic acid reduces MS in perforated tympanic membranes. A study in the rat. Ann Otol Rhinol Laryngol 2001;110:585-591.
21. Ozcan C, Polat G, Gorur K, et al. The effect of local administration of N-acetylcysteine in perforated rat tympanic membrane: an experimental study in MS. Pharmacol Res 2002;45:5-9.
22. Mattsson C, Hellstrom S. Inhibition of the development of MS by local administration of fenspiride, an anti-inflammatory drug. Eur Arch Otorhinolaryngol 1997;254:425-429.
23. Akbas Y, Pata YS, Gorur K, et al. The effect of L-carnitine on the prevention of experimentally induced MS in rats. Hear Res 2003;184:107-112.
24. Mattsson C, Stierna P, Hellstrom S. Treatment with dexamethasone arrests the development of MS after myringotomy. Am J Otol 2000;21:804-808.
25. Brodie HA, Chang PS, Chole RA. Dexamethasone inhibition of the development of dysplastic bony lesions in LP/J mice. Ann Otol Rhinol Laryngol 1993;102:814-817.
26. Gorur K, Ozcan C, Polat A, et al. The anti-oxidant and antiapoptotic activities of selenium in the prevention of MS in rats. J Laryngol Otol 2002;116:426-429.
27. Kazikdas KC, Uguz MZ, Erbil G, et al. The anti-oxidant effect of alpha-tocopherol in the prevention of experimentally induced myringosclerosis. Otol Neurotol 2006;27:882-886.
28. Polat S, Ozturk O, Uneri C, et al. Determination of reactive oxygen species in myringotomized tympanic membranes: effect of vitamin E treatment. Laryngoscope 2004;114:720-725.
29. Uneri C, Baglam T, Yazici M. The effect of Vitamin E treatment on the development of myringosclerosis after ventilation tube insertion. Int J Pediatr Otorhinolaryngol 2006;70:1045-1048.
30. Sprem N, Branica S, Dawidowsky K. Experimental hematotympanum: aspects to the tympanosclerosis development. Coll Antropol 2002;26:267-272.
31. Russell JD, Giles JJ. Tympanosclerosis in the rat tympanic membrane: an experimental study. Laryngoscope 2002;112:1663-1666.
32. Wielinga EW, Kuijpers W, Tonnaer EL, et al. An experimental model for tympanosclerosis. A preliminary report. Acta Otolaryngol 1988;105:537-542.
33. Santos PF, Leal MC, Peixoto C, et al. Otomicroscopic and histologic findings of induced myringosclerosis in rats: a critical study of an experimental model. Rev Bras Otorrinolaringol (Engl Ed) 2005;71:668-674.
34. Raustyte G, Caye-Thomasen P, Hermansson A, et al. Calcium deposition and expression of bone modelling markers in the tympanic membrane following acute otitis media. Int J Pediatr Otorhinolaryngol 2006;70:529-539.
35. Asiri S, Hasham A, al Anazy F, et al. Tympanosclerosis: review of literature and incidence among patients with middle-ear infection. J Laryngol Otol 1999;113:1076-1080.